Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
39.84
+1.49 (3.89%)
At close: Dec 20, 2024, 4:00 PM
40.34
+0.50 (1.25%)
After-hours: Dec 20, 2024, 6:36 PM EST
Aligos Therapeutics Employees
Aligos Therapeutics had 66 employees as of December 31, 2023. The number of employees decreased by 17 or -20.48% compared to the previous year.
Employees
66
Change (1Y)
-17
Growth (1Y)
-20.48%
Revenue / Employee
$90,864
Profits / Employee
-$1,165,955
Market Cap
147.87M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 66 | -17 | -20.48% |
Dec 31, 2022 | 83 | -10 | -10.75% |
Dec 31, 2021 | 93 | 19 | 25.68% |
Dec 31, 2020 | 74 | 13 | 21.31% |
Dec 31, 2019 | 61 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Nevro | 1,215 |
The Joint | 794 |
Metagenomi | 236 |
Seer, Inc. | 147 |
Vaxart | 109 |
Biomea Fusion | 103 |
Compugen | 68 |
Zura Bio | 15 |
ALGS News
- 8 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Appoints David Perry as Vice President of Business Development - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Present at Investor Conferences in October - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - GlobeNewsWire
- 3 months ago - Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Announces Reverse Stock Split - GlobeNewsWire